Multinational pharmaceutical firms, particularly U.S. giants, are increasingly recognizing China's burgeoning innovative drug sector as a strategic goldmine to bolster their global competitiveness.

Australia’s peak medicines industry group says it takes 466 days for approved medicines to become subsidised. Health Minister ...

A Petri dish in a lab. A genome spliced. A pathogen engineered. The spark of the next pandemic may not lie in nature – but in ...

and Pfizer to develop industry-wide standard for measuring CO2 from clinical trials A group comprising some of the biggest companies from across the global pharmaceuticals and cosmetics value ...

Sanofi, AbbVie, Johnson & Johnson (J&J), and other global pharmaceutical companies are opening their wallets to develop new treatments for autoimmune diseases. Autoimmune diseases occur when ...

Under the “reciprocal tariff” regime, aimed at major economies, in particular the European Union but many others as well, the ...

The comments come two weeks after American pharmaceutical giants, including Eli Lilly, represented by the Pharmaceutical Research and Manufacturers of America industry lobby group (PHrMA), wrote ...

Belgium is capitalising on a radiopharmaceutical sector investment boom. Pharma giants are acquiring radioligand therapy companies and expanding research areas.

This year's budget is being delivered at one of the most pivotal points in recent history, yet the federal government has ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...